• Careers
  • News
  • Publications
  • Contact Us
  • Company
    • About Us
    • Management Team
    • Board of Directors
    • Collaborations
    • Careers
    • Contact Us
  • Therapeutic Areas
    • Oncology
    • Cystic Fibrosis
    • Publications
  • Programs
    • Pipeline
    • Glutaminase Inhibitor Telaglenastat
    • Arginase Inhibitor Oncology
    • Arginase Inhibitor
      Cystic Fibrosis
    • CD73 Inhibitor
      CB-708
    • IL4I1 Inhibitor
  • Clinical Trials
    • Clinical Trials Overview
    • Expanded Access
  • Media & Investors
    • Corporate Profile
    • Press Releases
    • Event & Presentations
    • Stock Information
    • Financial Information
      • Overview
      • SEC Filings
      • Ownership Summary
    • Analyst Coverage
    • Corporate Governance
      • Highlights
      • Board of Directors
      • Management Team
      • Committee Composition
    • Shareholder Services
      • Investor FAQs
      • E-mail Alerts
    • Proxy & Annual Report
    • Contact Us
  • Careers
  • News
  • Publications
  • Contact Us

Targeting cancer, differently.

Our onco-metabolism approach brings
an enhanced perspective to cancer.

Learn More

Targeting cancer, differently.

Our onco-metabolism approach brings
an enhanced perspective to cancer.

Learn More

Targeting cancer, differently.

Our onco-metabolism approach brings
an enhanced perspective to cancer.

Learn More

Development Pipeline

Calithera is pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.

Learn More

Development Pipeline

Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.

Learn More

Culture

Therapeutic Areas

Recent News

March 16, 2021

Calithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent Highlights

March 12, 2021

UPDATE – Calithera Biosciences to Report Fourth Quarter 2020 Financial Results on Tuesday, March 16, 2021

March 10, 2021

Calithera Biosciences to Report Fourth Quarter 2021 Financial Results on Tuesday, March 16, 2021

March 2, 2021

Calithera to Present at the H.C. Wainwright Virtual Global Life Sciences 2021 Conference

February 22, 2021

Calithera to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

View All
Company
  • About Us
  • Management Team
  • Board of Directors
  • Collaborations
  • Careers
  • Contact Us
Therapeutic Areas
  • Oncology
  • Cystic Fibrosis
  • Publications
Programs
  • Pipeline
  • Glutaminase Inhibitor Telaglenastat (CB-839)
  • Arginase Inhibitor Oncology
  • Arginase Inhibitor Cystic Fibrosis
  • CD73 Inhibitor CB-708
  • IL4I1 Inhibitor
Clinical Trials
  • Clinical Trial Overview
  • Expanded Access
Media & Investors
  • Corporate Profile
  • Press Release
  • Events & Presentations
  • Stock Information
  • Financial Information
  • Analyst Coverage
  • Corporate Governance
  • Shareholder Services
  • Proxy & Annual Report
  • Contact Us
© 2021 Calithera Biosciences, Inc. All rights reserved.
ETHICS & COMPLIANCEPRIVACY POLICYLEGAL TERMS OF USE
  • Contact Us
  • News
CALITHERA® and the Calithera logos are trademarks or registered trademarks of Calithera Biosciences, Inc.
CALITHERA® and the Calithera logos are trademarks or registered trademarks of Calithera Biosciences, Inc.